Coronavirus: Human testing for Johnson & Johnson COVID-19 vaccine by Sept

  • Johnson & Johnson said the coronavirus vaccine may be ready for emergency use by early next year
  • J&J began working on the investigational vaccine, Ad26 SARS-CoV-2 in January using the same technology it used to develop a candidate vaccine for Ebola

AFP
Updated31 Mar 2020
Johnson & Johnson has signed an agreement with the US government's Biomedical Advanced Research and Development Authority to invest $1 billion in the effort, it said in a statement.
Johnson & Johnson has signed an agreement with the US government’s Biomedical Advanced Research and Development Authority to invest $1 billion in the effort, it said in a statement.(Photo: Reuters)

Johnson & Johnson said on Monday it had selected a lead candidate vaccine for the new coronavirus that would move to human trials by September and could be ready for emergency use by early next year.

The pharmaceutical company has signed an agreement with the US government's Biomedical Advanced Research and Development Authority to invest $1 billion in the effort, it said in a statement.

J&J began working on the investigational vaccine, Ad26 SARS-CoV-2 in January using the same technology it used to develop a candidate vaccine for Ebola.

It uses a deactivated version of the virus to try to trigger a human immune response.

The company said it was expanding its global manufacturing capacity both in the US and in other countries, to help it supply more than a billion doses of its vaccine around the world.

CEO Alex Gorsky said the company was "well positioned through our combination of scientific expertise, operational scale and financial strength to bring our resources in collaboration with others to accelerate the fight against this pandemic."

J&J is also working on antiviral treatments against the coronavirus.

Separately, the US pharmaceutical Moderna has already moved into human trials for its vaccine candidate, as has China's CanSinoBIO.

There are currently no approved vaccines or treatments for the disease.

Several treatments are being investigated, including the antiviral remdesivir and antimalarial drugs chloroquine and hydroxychloroquine, but it is not yet clear whether they add anything to standard care.

Catch all the Business News, Market News, Breaking News Events and Latest News Updates on Live Mint. Download The Mint News App to get Daily Market Updates.MoreLess
HomeNewsworldCoronavirus: Human testing for Johnson & Johnson COVID-19 vaccine by Sept

Most Active Stocks

Bharat Electronics

309.55
10:29 AM | 14 JUN 2024
8.6 (2.86%)

Indian Oil Corporation

170.30
10:25 AM | 14 JUN 2024
1.2 (0.71%)

HDFC Bank

1,597.45
10:28 AM | 14 JUN 2024
16.55 (1.05%)

State Bank Of India

840.20
10:29 AM | 14 JUN 2024
-3.7 (-0.44%)
More Active Stocks

Market Snapshot

  • Top Gainers
  • Top Losers
  • 52 Week High

JK Paper

490.70
10:25 AM | 14 JUN 2024
44.35 (9.94%)

KRBL

310.05
10:22 AM | 14 JUN 2024
23.05 (8.03%)

Poly Medicure

2,003.00
09:59 AM | 14 JUN 2024
142.9 (7.68%)

KEC International

935.20
10:25 AM | 14 JUN 2024
66.25 (7.62%)
More from Top Gainers

Recommended For You

    More Recommendations

    Gold Prices

    • 24K
    • 22K
    Bangalore
    73,950.000.00
    Chennai
    73,160.000.00
    Delhi
    73,663.000.00
    Kolkata
    73,016.000.00

    Fuel Price

    • Petrol
    • Diesel
    Bangalore
    102.86/L0.00
    Chennai
    100.75/L0.00
    Kolkata
    103.94/L0.00
    New Delhi
    94.72/L0.00
    OPEN IN APP
    HomeMarketsPremiumInstant LoanGet App